Treatment
Lenvatinib clinical trials
We’re tracking 150 recruiting studies that include Lenvatinib, each written for real people, not researchers, below.
Recruiting studies
- NCT05738616RecruitingPhase 3
Testing lenvatinib plus TACE and immunotherapy before liver surgery
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
Chengdu, SichuanAges 18–75 - NCT05823311RecruitingPhase 3
Test lenvatinib and immunotherapy plus chemo for bile duct cancer
This Phase 3 study tests whether a combination of lenvatinib, an immunotherapy medicine (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) works better for advanced bile duct cancer that cannot be fully removed by surgery. It may help people live longer or control the cancer for longer.
Hangzhou, ZhejiangAges 18–75 - NCT05617859RecruitingPhase 2
Lenvatinib treatment for advanced bone or soft tissue sarcoma
This trial tests lenvatinib to shrink or control advanced bone or soft tissue sarcoma that can’t be safely treated with surgery. You may be eligible if your cancer has measurable spots and you’ve had specific prior drug treatments without a durable response.
Zhengzhou, HenanAges 10–70 - NCT05057845RecruitingPhase 2
Freezing treatment plus immunotherapy and a pill for liver cancer
This trial tests whether freezing (cryoablation) combined with tislelizumab and lenvatinib can help shrink advanced liver cancer and improve outcomes after earlier treatments stopped working or caused side effects. It may be an option if your cancer can’t be removed with surgery and you’ve already tried one prior systemic (whole-body) treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05098847RecruitingPhase 2
Freezing liver tumors plus anti-cancer drugs for spread cancer
This trial tests whether freezing (cryoablation) liver metastases works better when combined with immunotherapy (sintilimab) and a targeted pill (lenvatinib). It’s for people whose cancer has spread to the liver and has not responded to earlier treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06673628RecruitingPhase 2
Pembrolizumab plus lenvatinib for skin angiosarcoma
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for people with a rare skin cancer called cutaneous angiosarcoma that cannot be removed by surgery. The goal is to see if the combination shrinks the tumor or slows its growth.
KashiwaAges 18–85 - NCT07110064RecruitingPhase 2
A new combo therapy for advanced pancreatic cancer
This trial tests a combination of three drugs (QL1706, lenvatinib, and chemotherapy) as the first treatment for people with advanced pancreatic cancer that has spread to other parts of the body. It aims to see if this combination is safe and effective.
NanjingAges 18 years+ - NCT06986785RecruitingPhase 2
Study of new drug combinations for advanced liver cancer
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05789667Recruiting
Study lenvatinib effects by patient gender in thyroid cancer
This study looks at whether safety and treatment results with lenvatinib differ between genders for people with iodine-refractory differentiated thyroid cancer. If you have already been treated with lenvatinib and meet the basic requirements, you may be asked to join after consenting.
RomeAges 18 years+ - NCT06904014RecruitingPhase 2
Testing a new drug combo before surgery for liver cancer
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
Jinan, ShandongAges 18–70 - NCT06860477RecruitingPhase 2
Freezing therapy plus targeted drugs vs. chemotherapy for advanced bile duct cancer
This trial tests whether a combination of cryoablation (freezing tumors) and two drugs (lenvatinib and tislelizumab) works better than a standard chemotherapy regimen (FOLFOX) for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer in the liver) that has not responded to or has stopped responding to one prior therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07099274RecruitingPhase 2
Combination treatment for advanced liver cancer
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07683949Enrolling by invitationPhase 1/Phase 2
Capecitabine plus lenvatinib for advanced colorectal cancer
This trial tests a combination of two oral drugs, capecitabine and lenvatinib, in people with advanced colorectal cancer that has stopped responding to three common chemotherapy drugs. It aims to see if this new combination can help shrink tumors or slow cancer growth.
Seongnam-si, Out of USAges 19–99 - NCT07096609RecruitingPhase 1/Phase 2
Lenvatinib for GIST after imatinib, sunitinib, and regorafenib
This trial tests a drug called lenvatinib for people with advanced GIST that has not responded to three previous treatments. It may offer a new option if standard therapies have stopped working or caused severe side effects.
SeoulAges 20 years+ - NCT07475026RecruitingPhase 3
Combination therapy before surgery for high-risk liver cancer
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
TianjinAges 18–75 - NCT05603910RecruitingPhase 1
Drug and radiation combo for recurrent pelvic endometrial cancer
This study tests a combination of two drugs (lenvatinib and pembrolizumab) plus focused radiation to the pelvis for a specific type of endometrial cancer that has returned or cannot be surgically removed. The goal is to see if this treatment is safe and effective for tumors that are pMMR and limited to the pelvic area.
Miami, FloridaAges 18 years+ - NCT06192797RecruitingPhase 2
Combination therapy for unresectable bile duct cancer
This trial tests a combination of three treatments—a liver-directed chemotherapy infusion (HAIC), a targeted therapy pill (lenvatinib), and an immunotherapy (pucotenlimab)—to try to shrink bile duct cancers that cannot be surgically removed. The goal is to make the cancer surgically removable or to control it for as long as possible.
Wuhan, HubeiAges 18 years+ - NCT07704177RecruitingPhase 2
A study of trastuzumab rezetecan plus two other drugs for advanced bile duct cancer
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has HER2 protein on its cells. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT04427293RecruitingPhase 1
Testing lenvatinib and pembrolizumab before breast cancer surgery
This early-phase trial tests whether lenvatinib plus pembrolizumab given before surgery can help treat early-stage triple-negative breast cancer. If you qualify, you would receive study medicines before your planned operation to remove the tumor and nearby lymph nodes.
Chicago, IllinoisAges 18 years+ - NCT04519151RecruitingPhase 2
Pembrolizumab plus lenvatinib for ovarian cancer that returned
This Phase 2 trial tests whether pembrolizumab plus lenvatinib can shrink ovarian cancer that has come back after platinum chemotherapy. You may be eligible if your cancer returned after a certain “time off” from prior treatment and you meet key health and safety requirements.
Ramat GanAges 18 years+ - NCT04803318RecruitingPhase 2
Test of three targeted medicines for advanced solid tumors
This Phase 2 study tests trametinib plus everolimus plus lenvatinib in people with advanced solid tumors that have come back or cannot be treated anymore. It aims to control tumor growth and symptoms when standard options have not worked.
Guangzhou, GuangdongAges 18–85 - NCT04865887RecruitingPhase 2
Pembrolizumab plus lenvatinib for advanced cervical cancer
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07594015RecruitingPhase 2
Pembrolizumab and Lenvatinib for Recurrent Endometrial Cancer
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for endometrial cancer that has come back after initial treatment with chemotherapy and immunotherapy. The study focuses on a specific type of cancer based on genetic testing and may help patients whose cancer didn't respond to standard first-line treatment.
Miami, FloridaAges 18 years+ - NCT04951947RecruitingPhase 2
Study drug plus lenvatinib for advanced small-cell lung cancer
This Phase 2 trial tests JS-201 combined with lenvatinib in people with extensive-stage small-cell lung cancer whose first-line treatment didn’t work. It may help by trying a new combination approach after prior therapy failure.
Changsha, HunanAges 18–75
Common questions
- Are there clinical trials studying Lenvatinib?
- Yes. Clin2 currently lists 150 recruiting studies that include Lenvatinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Lenvatinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Lenvatinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Lenvatinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.